SLC5A1 and type 2 diabetes mellitus: As evidenced by the aforementioned study involving type 2 diabetes mellitus [10], Me4FDG may be able to be potentially employed to investigate the contribution of the renal system to obesity-related diseases, as Me4FDG is able to determine the threshold of renal glucose reabsorption, a process carried out exclusively by the two transporters SGLT1 and SGLT2.